• BrainsWay flagged a new peer-reviewed secondary analysis showing Deep TMS reduced suicidal ideation in patients with major depressive disorder.
• Results have already been published in the Journal of Affective Disorders, based on a previously reported multisite randomized trial.
• Both the SWIFT accelerated protocol and standard once-daily treatment produced improvement, with faster relief reported under SWIFT.
• Findings support Deep TMS’s potential role in suicidality, though the device remains FDA-cleared only for major depressive disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brainsway Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005759), on August 27, 2026, and is solely responsible for the information contained therein.